How Nutromics is Integrating Continuous Monitoring into Diagnostics to Transform Patient Care

Nutromics is an Australian-born diagnostic company determined to eliminate preventable deaths caused by insufficient continuous monitoring. Since its founding in 2017, the company has focused on tackling a fundamental gap in the way chronic health conditions are tracked over time.

Peter Vranes, co-founder and CEO, highlights a core flaw in current healthcare diagnostics. He explains, “Healthcare largely depends on isolated tests — blood draws, scans, or biopsies — taken at moments in time. These provide snapshots, but not the full story.” These snapshots miss the subtle and rapid changes in a patient’s condition that often signal worsening disease or new complications. Without continuous data, clinicians respond only after symptoms become acute, losing valuable time for early intervention.

A Wearable Patch with a Practical Edge

The driving force behind Nutromics is its wearable patch — a small device featuring DNA-based sensors mounted on microneedles that just penetrate below the skin surface. Peter describes it plainly: “By coating the tips of microneedles with DNA sensors, we can detect and measure multiple biomarkers — from inflammatory proteins to metabolic compounds — continuously and simultaneously.”

This capability offers promise for managing complex diseases like heart failure, diabetes, and autoimmune disorders, where shifts in biomarkers indicate critical changes in health status. The patch prioritizes patient comfort and convenience. Unlike bulky hospital equipment or frequent finger-prick tests, Nutromics’ device is discreet, pain-free, and designed for extended wear. It streams data securely in real time to healthcare providers or directly to patients.

Developing such a technology demanded years of refinement. The team balanced sensitivity, accuracy, durability, and cost to create a product capable of reliable multiplexed monitoring — a feat few competitors have matched. Peter stresses that continuous, multiplexed monitoring represents a significant shift in diagnostics. “It moves testing from labs and hospitals into everyday life, giving care teams the chance to act faster and with greater precision.”

Recognition and Growth Fuel Ambition

Nutromics’ advances have garnered attention and substantial funding. The company has raised US$27 million, enabling expansion of research, development, and clinical validation. This financial backing supports operations across Australia and the United States and the recruitment of specialist teams.

The company’s innovation has earned several accolades, including being named among the Top 50 Australian inventions changing the world and winning Technology Platform Solution of the Year at the national iAwards. Peter sees these honors as more than trophies: “They open doors with investors, healthcare institutions, and regulators. Credibility is crucial in the MedTech sector to build trust and drive adoption.”

Participation in accelerator programs like LaunchVic’s 30x30 initiative has also proved invaluable, offering mentorship and insights into the complexities of bringing medical technologies to market. Nutromics is preparing for broader clinical trials and regulatory clearances in both Australia and the US. Peter underlines the importance of these steps: “We work closely with clinicians and regulators to ensure the technology meets the highest standards. It’s a rigorous process but one that must be done properly.”

Overcoming Challenges to Advance Diagnostics

Innovation in diagnostics comes with significant hurdles. Peter is candid about the technical, regulatory, and operational difficulties Nutromics has faced. “Creating a device that delivers continuous, accurate data across multiple targets is complex. We refined our sensor chemistry, manufacturing, and data analysis several times.”

Proving safety and efficacy is just part of the process; the company must also demonstrate that the device improves clinical decisions and patient outcomes. Scaling production while maintaining quality demands considerable investment and expertise. Nutromics is developing the necessary infrastructure to meet these demands without losing flexibility.

Introducing continuous monitoring into everyday healthcare requires adjustments in clinical practice. Doctors need to understand how to interpret ongoing data streams and use this information in treatment plans. Peter foresees a healthcare model where continuous diagnostics empower both clinicians and patients. “We want patients to be more informed and in control, while clinicians have tools to make earlier and better decisions.”

To support this transition, Nutromics is working on digital platforms and training programs designed to facilitate adoption and integration into healthcare systems.

Committed to Reducing Preventable Deaths

Nutromics is driven by a commitment to save lives by catching disease progression early. Peter’s words underline the urgency: “Every preventable death is a failure of our system. If we can give patients and clinicians constant insight into health changes, we can intervene sooner — preventing emergencies before they happen.”

By delivering continuous, multiplexed biomarker data through a wearable patch, Nutromics aims to rewrite the diagnostic playbook and establish new standards for patient care. This vision is grounded in responsibility and practical science, steering clear of hype. The company builds a future where healthcare decisions rest on real-time evidence and preventable tragedies are rare.

Peter concludes, “The technology is ready. Now it’s about bringing it to those who need it most — patients worldwide.”

Peter Vranes, Co-Founder & CEO, Nutromics

We are working closely with clinicians and regulators to ensure our technology meets the highest standards.